Lpl Financial LLC Cor Medix Inc. Transaction History

Lpl Financial LLC

$218 Billion
Q3 2024

A detailed history of Lpl Financial LLC transactions in Cor Medix Inc. stock. As of the latest transaction made, Lpl Financial LLC holds 56,765 shares of CRMD stock, worth $484,773. This represents 0.0% of its overall portfolio holdings.

Number of Shares

56,765

Previous 48,078 18.07%

Holding current value

$484,773

Previous $208,000 120.19%

% of portfolio

0.0%

Previous 0.0%

12 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2024 Nov 08, 2024	BUY	$3.64 - $8.23 $31,620 - $71,494	8,687 Added 18.07%	56,765 $458,000
Q2 2024 Aug 07, 2024	SELL	$4.08 - $6.39 $17,633 - $27,617	-4,322 Reduced 8.25%	48,078 $208,000
Q1 2024 May 10, 2024	BUY	$2.94 - $4.24 $89,964 - $129,744	30,600 Added 140.37%	52,400 $222,000
Q4 2023 Feb 14, 2024	BUY	$3.0 - $4.01 $3,000 - $4,010	1,000 Added 4.81%	21,800 $81,000
Q3 2023 Nov 13, 2023	BUY	$3.6 - $4.46 $2,880 - $3,568	800 Added 4.0%	20,800 $76,000
Q4 2022 Feb 07, 2023	SELL	$2.81 - $4.45 $26,141 - $41,398	-9,303 Reduced 31.75%	20,000 $84,000
Q3 2022 Nov 14, 2022	BUY	$2.82 - $7.52 $47,883 - $127,689	16,980 Added 137.79%	29,303 $83,000
Q1 2022 May 16, 2022	BUY	$3.83 - $6.24 $47,197 - $76,895	12,323 New	12,323 $68,000
Q1 2021 May 14, 2021	SELL	$6.84 - $17.58 $120,589 - $309,935	-17,630 Closed	0 $0
Q4 2020 Feb 12, 2021	SELL	$5.0 - $9.15 $3,285 - $6,011	-657 Reduced 3.59%	17,630 $131,000
Q3 2020 Nov 09, 2020	BUY	$3.96 - $6.15 $18,018 - $27,982	4,550 Added 33.12%	18,287 $110,000
Q2 2020 Aug 13, 2020	BUY	$3.08 - $6.56 $42,309 - $90,114	13,737 New	13,737 $87,000

Others Institutions Holding CRMD

# of Institutions

105

Shares Held

17.4M

Call Options Held

134K

Put Options Held

441K

View Full List

About CorMedix Inc.

Ticker CRMD
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 41,208,200
Market Cap $352M
Description
CorMedix Inc., a biopharmaceutical company, focuses on developing and commercializing therapeutic products for the prevention and treatment of infectious and inflammatory diseases in the United States and internationally. Its lead product candidate is DefenCath/Neutrolin, a novel anti-infective solution for the reduction and prevention of cathet...

More about CRMD

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Lpl Financial LLC, based on Form 13F filings with the SEC.

News

Stay updated on Lpl Financial LLC with notifications on news.

Account

Lpl Financial LLC Cor Medix Inc. Transaction History